Needham analyst Michael Matson reiterated a Buy rating on Stryker today and set a price target of $448.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Buy rating due to a combination of factors including Stryker’s impressive financial performance and strategic initiatives. The company exceeded expectations in its second-quarter revenue and earnings per share, prompting an upward revision in its 2025 organic revenue and EPS guidance. Additionally, Stryker has effectively managed its tariff impact, reducing it from $200 million to $175 million, with plans to fully offset this cost.
Furthermore, Stryker demonstrated robust growth across its various business segments, supported by high procedure volumes, the introduction of new products, and a strong capital equipment backlog. The company’s organic sales growth remained stable, and both its gross and operating margins showed significant year-over-year improvements. These factors, along with the successful execution of new product launches, have contributed to the strong revenue growth, leading to an increased price target and the reaffirmation of the Buy rating.
In another report released today, Barclays also maintained a Buy rating on the stock with a $443.00 price target.